# US 2019/0167611 A1 · Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167611 A1 - Document ID: US20190167611A1 - Status: Published application - Kind: A1 - Application number: 16/321,240 - Filed: 2017-07-28 - Published: 2019-06-06 - Earliest claimed: 2016-07-29 - Assignees: Biogen Chesapeake LLC - Applicants: Biogen Chesapeake LLC - Inventors: Sven JACOBSON; Thomas MACALLISTER - Web page: https://patentgrep.com/patent/US20190167611A1 ## CPC - A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64) - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) - A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A method of treating or preventing amyloid related imaging abnormalities (ARIA) in patients receiving one or more course of medical treatment for Alzheimer's Disease includes administrating a SUR1-TRPM4 channel inhibitor, such as glyburide, in an amount effective to prevent the formation or reduce the size of one or more ARIAs in the brain. ## Claims ### Claim 1 A method of treating or preventing amyloid related imaging abnormalities (ARIA) in a subject undergoing at least one course of medical treatment for Alzheimer's Disease, comprising administering a SUR1-TRPM4 channel inhibitor to the subject, wherein the SUR1-TRPM4 channel inhibitor is administered in an amount effective to prevent the formation or reduce the size of one or more ARIAs in the brain. ### Claim 2 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor comprises at least one of glyburide, 4-trans-hydroxy-glibenclamide, 3-cis-hydroxyglibenclamide, tolbutamide, chlorpropamide, tolazamide, repaglinide, nateglinide, meglitinide, midaglizole, tolazamide, gliquidone, LY397364, LY389382, glyclazide, glimepiride, 9-phenantrol, fluflenamic acid, riluzole, spermine, adenosine, quinine, quinidine, diphenylamine-2-carboxylic acid, 3′,5′-dichlorodiphenylamine-2-carboxylic acid, 5-nitro-2-(3-phenylpropyl-amino)-benzoic acid, MPB-104, metabolites that interact with SUR1, or combinations thereof. ### Claim 3 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor comprises glyburide. ### Claim 4 (depends on 1) The method of claim 1, wherein the one or more ARIAs are induced by an anti-beta-amyloid treatment. ### Claim 5 (depends on 1) The method of claim 1, wherein the size of one or more ARIAs in the brain is measured using at least one of Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), Positron Emission Tomography (PET), or Functional Near-Infrared Spectroscopy (FNIR). ### Claim 6 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered prior to at least once course of said medical treatment. ### Claim 7 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered about 6 hours or less prior to the initiation of said medical treatment. ### Claim 8 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered for about 1 hours to about 96 hours. ### Claim 9 (depends on 1) The method of claim 1, wherein at least a portion of the SUR1-TRPM4 channel inhibitor is administered during said medical treatment. ### Claim 10 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered via one or more continuous infusions. ### Claim 11 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered via a transdermal patch or gel. ### Claim 12 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered via injection. ### Claim 13 (depends on 1) The method of claim 1, wherein the SUR1-TRPM4 channel inhibitor is administered orally. ### Claim 14 (depends on 1) The method of claim 1, wherein the amount of the SUR1-TRPM4 channel inhibitor is about 0.05 mg/day to about 3.0 mg/day. ### Claim 15 (depends on 1) The method of claim 1, wherein the administration of the SUR1-TRPM4 channel inhibitor achieves a SUR1-TRPM4 channel inhibitor plasma level of about 0.4 ng/mL to about 5 ng/mL. ### Claim 16 (depends on 1) The method of claim 1, wherein the administration of the SUR1-TRPM4 channel inhibitor achieves a steady-state SUR1-TRPM4 channel inhibitor concentration of about 3.0 ng/mL to about 30.0 ng/mL. ### Claim 17 (depends on 1) The method of claim 1, wherein the administration of the SUR1-TRPM4 channel inhibitor achieves a Cmax of the SUR1-TRPM4 channel inhibitor of about 1 ng/mL to about 30 ng/mL.